NCT07301437尚未招募4 期
A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine0 个研究点目标入组 120 人开始时间: 2026年5月1日最近更新:
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
- 主要终点
- weight loss
研究概览
简要总结
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
- •Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
- •No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
排除标准
- •Allergy to liraglutide, orlistat or excipients
- •Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
- •Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
- •Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
- •Pregnant or lactating women
- •Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).
研究组 & 干预措施
experimental group
Experimental
干预措施: liraglutide combined with orlistat (Drug)
control group
Active Comparator
干预措施: liraglutide monotherapy (Drug)
结局指标
主要结局
weight loss
时间窗: 6 months
次要结局
未报告次要终点
研究者
相似试验
招募中
2 期
FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity2023-503753-35-01Region Hovedstaden, Region Hovedstaden100
招募中
3 期
Weight loss in people living with overweight or obesity following treatment with cagrilintide2024-519530-24-00Novo Nordisk A/S120
招募中
3 期
Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide2024-519531-41-00Novo Nordisk A/S130
进行中（未招募）
1 期
Weight loss before weight loss surgery in patients with fatty liverObesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complications after the procedure.EUCTR2020-000220-19-ATVerein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung der Krankenanstalt Rudolfstiftung62
进行中（未招募）
1 期
Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patientsEUCTR2020-000043-31-FRGroupe Hospitalier Paris Saint-Joseph30